BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3925619)

  • 1. The use of vimentin antibodies in the diagnosis of malignant mesothelioma.
    Jasani B; Edwards RE; Thomas ND; Gibbs AR
    Virchows Arch A Pathol Anat Histopathol; 1985; 406(4):441-8. PubMed ID: 3925619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma.
    Mullink H; Henzen-Logmans SC; Alons-van Kordelaar JJ; Tadema TM; Meijer CJ
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 52(1):55-65. PubMed ID: 2435052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry in the diagnosis of malignant mesothelioma.
    Pfaltz M; Odermatt B; Christen B; Rüttner JR
    Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
    Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J
    J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies.
    Noguchi M; Nakajima T; Hirohashi S; Akiba T; Shimosato Y
    Hum Pathol; 1989 Jan; 20(1):53-7. PubMed ID: 2912874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
    Abutaily AS; Addis BJ; Roche WR
    J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma.
    Holden J; Churg A
    Am J Surg Pathol; 1984 Apr; 8(4):277-9. PubMed ID: 6201076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
    Sheibani K; Battifora H; Burke JS
    Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach.
    Battifora H; Kopinski MI
    Cancer; 1985 Apr; 55(8):1679-85. PubMed ID: 2579718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma.
    Churg A
    Am J Surg Pathol; 1985 May; 9(5):360-5. PubMed ID: 2418692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
    Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
    Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
    Wirth PR; Legier J; Wright GL
    Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
    Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A
    Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
    al-Saffar N; Hasleton PS
    Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.
    Skov BG; Lauritzen AF; Hirsch F; Nielsen HW
    Histopathology; 1994 Jun; 24(6):553-7. PubMed ID: 8063283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.
    Moch H; Oberholzer M; Dalquen P; Wegmann W; Gudat F
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):19-27. PubMed ID: 8212530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas.
    Gaffey MJ; Mills SE; Swanson PE; Zarbo RJ; Shah AR; Wick MR
    Am J Surg Pathol; 1992 Jun; 16(6):593-9. PubMed ID: 1599037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma.
    Chang K; Pai LH; Pass H; Pogrebniak HW; Tsao MS; Pastan I; Willingham MC
    Am J Surg Pathol; 1992 Mar; 16(3):259-68. PubMed ID: 1599018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.